EGFR and non-small cell lung carcinoma: As an example of potential circumvention of osimertinib resistance, co-targeting EGFR-T790M with osimertinib plus STAT3/Src with a non-marketed, nonpeptidic small molecule, STAT3 inhibitor aminocarbonyl-amino-5-4-fluorophenyl-3-thiophenecarboxamide, was synergistic in two EGFR-mutant NSCLC cell lines—PC9 harboring EGFR exon 19 deletion, E746-A750, and H1975 harboring both sensitizing L858R and resistant T790M mutations [16].